Abstract
Overexpression of cyclooxygenase-2 (COX-2) has been associated with hepatocarcinogenesis. Inhibitors of COX-2 have proapoptotic and antiproliferative effects on malignant tumors and inhibit tumor invasion to the surrounding tissues. We report here a case of complete regression of advanced hepatocellular carcinoma (HCC) during COX-2 inhibitor administration. An eighty-year-old female was diagnosed as an advanced HCC, which was associated with HCV infection. She received COX-2 inhibitor for 3 months due to degenerative arthritis of both knees. Tumor enhancement on arterial phase CT completely disappeared without specific treatment for the HCC, and the tumor size decreased on the follow-up CT scan.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Hepatocellular / drug therapy*
-
Celecoxib
-
Cyclooxygenase 2 Inhibitors / administration & dosage
-
Cyclooxygenase 2 Inhibitors / therapeutic use*
-
Diclofenac / administration & dosage
-
Diclofenac / analogs & derivatives
-
Diclofenac / therapeutic use
-
Female
-
Humans
-
Lactones / administration & dosage
-
Lactones / therapeutic use
-
Liver Neoplasms / drug therapy*
-
Pyrazoles / administration & dosage
-
Pyrazoles / therapeutic use
-
Sulfonamides / administration & dosage
-
Sulfonamides / therapeutic use
-
Sulfones / administration & dosage
-
Sulfones / therapeutic use
Substances
-
Cyclooxygenase 2 Inhibitors
-
Lactones
-
Pyrazoles
-
Sulfonamides
-
Sulfones
-
rofecoxib
-
Diclofenac
-
Celecoxib
-
aceclofenac